Incyte Corporation
COMBINATION THERAPY WITH AN ANTI-CD19 ANTIBODY AND PARSACLISIB
Last updated:
Abstract:
The present disclosure describes a combination of an anti-CD19 antibody and parsaclisib for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.
Status:
Application
Type:
Utility
Filling date:
30 Nov 2021
Issue date:
4 Aug 2022